Literature DB >> 10049966

Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis.

P W Hiatt1, S C Grace, C A Kozinetz, S H Raboudi, D G Treece, L H Taber, P A Piedra.   

Abstract

OBJECTIVE: To determine the effect of respiratory viral infections on pulmonary function in infants with cystic fibrosis (CF) after the respiratory virus season (October through March).
METHODS: Recruitment was for one respiratory virus season during a 3-year span, 1988 to 1991, with reenrollment allowed; 22 infants <2 years of age with CF (30 patient-seasons) and 27 age-matched controls (28 patient-seasons) participated. Primary outcome variables were preseason and postseason pulmonary function tests and serology for viral antibodies. Twice-weekly telephone calls screened for respiratory symptoms. The presence of respiratory symptoms triggered a home visit and an evaluation for upper or lower (LRTI) respiratory tract infection. A nasopharyngeal sample for viral culture was performed with each visit.
RESULTS: Controls and CF infants each had a mean of 5.3 acute respiratory illnesses; CF infants were four times more likely to develop an LRTI compared with controls (odds ratio, 4.6; 95% confidence interval, 1.3 and 16.5). Three of 7 (43%) CF infants with respiratory syncytial virus infection (documented by culture) required hospitalization. Controls had no association between respiratory illness and postseason pulmonary function. For CF infants, reduced postseason maximal flow at functional residual capacity (V'maxFRC) was associated with two interactions, ie, respiratory syncytial virus infection and LRTI, and male sex and LRTI; increased gas trapping (FRC) was associated with an interaction between respiratory syncytial virus and LRTI and day care. Postseason pulmonary function tests were obtained a mean of 3. 2 months after final LRTI.
CONCLUSIONS: Infants with CF incurring respiratory virus infection are at significant risk for LRTI, for hospitalization, and for deterioration in lung function that persists months after the acute illness.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10049966     DOI: 10.1542/peds.103.3.619

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  58 in total

Review 1.  Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis.

Authors:  Melissa B Miller; Peter H Gilligan
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

Review 2.  Atypical cystic fibrosis--diagnostic and management dilemmas.

Authors:  Colin Wallis
Journal:  J R Soc Med       Date:  2003       Impact factor: 5.344

3.  Respiratory syncytial virus pathophysiology and affect of palivizumab in special populations: cystic fibrosis and immunosuppression.

Authors:  Michael E Speer
Journal:  J Pediatr Pharmacol Ther       Date:  2011-04

Review 4.  Spectrum of viral infections in patients with cystic fibrosis.

Authors:  H Frickmann; S Jungblut; T O Hirche; U Groß; M Kuhns; A E Zautner
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2012-09-10

Review 5.  Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.

Authors:  Karen A Robinson; Olaide A Odelola; Ian J Saldanha
Journal:  Cochrane Database Syst Rev       Date:  2016-07-20

6.  Volatile fingerprinting of Pseudomonas aeruginosa and respiratory syncytial virus infection in an in vitro cystic fibrosis co-infection model.

Authors:  Giorgia Purcaro; Christiaan A Rees; Jeffrey A Melvin; Jennifer M Bomberger; Jane E Hill
Journal:  J Breath Res       Date:  2018-07-03       Impact factor: 3.262

7.  A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.

Authors:  Bosco A Paes; Ian Mitchell; Anna Banerji; Krista L Lanctôt; Joanne M Langley
Journal:  Can Respir J       Date:  2011 Mar-Apr       Impact factor: 2.409

Review 8.  Monitoring early inflammation in CF. Infant pulmonary function testing.

Authors:  Jack K Sharp
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

9.  Respiratory syncytial virus prophylaxis in cystic fibrosis: the Canadian registry of palivizumab data (2005-2016).

Authors:  Ian Mitchell; S K Wong; B Paes; M Ruff; C Bjornson; A Li; K L Lanctôt
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-05-04       Impact factor: 3.267

10.  Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?

Authors:  Candice Bjornson; Parco Chan; Abby Li; Bosco Paes; Krista L Lanctôt; Ian Mitchell
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-03-19       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.